Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Part of paid clinical trials in Chapel Hill, North Carolina.
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Study ID
- NCT04099290
- Status
- Recruiting
Conditions
- Carcinoma, Squamous Cell
- Head and Neck Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Blood and tumor samples — OTHERBlood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
Study Details
Circulating tumor DNA (ctDNA) is a blood-based test that measures dying or dead cancer cells that are already circulating in the blood. In this study, the investigators will enroll patients who are planning to receive surgery to remove their head and neck cancer. The investigators are interested to learn how ctDNA levels change with surgery and over the course of time. The investigators also want to determine if there are certain features of the tumor or the patient themselves that might cause ctDNA to be higher than other patients. Also, the investigators want to explore if the detection of ctDNA following surgery is related to cancer recurrence.
Key Dates
- Start date
- Jan 14, 2020
- Status verified
- Feb 2026
- Primary completion
- Feb 1, 2027
- Completion
- Feb 1, 2027
Study Design
- Enrollment
- 50 participants (estimated)
Primary Outcome Measure
Rate of tumor-specific mutation in pre-operative circulating tumor DNA of patients with locally-advanced HNSCC who are receiving surgery for treatment of their primary tumor [ Time Frame: Time of consent ]
Central Contacts
- Siddharth Sheth, MD(919) 966-3856
- Rebecca Green, MSW(984) 974-8440
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | Siddharth Sheth, MD |
Find similar trials in Chapel Hill, NC
Related Studies
- Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · Recruiting · Bicara Therapeutics · La Jolla, California
- Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCCRecruiting · UNC Lineberger Comprehensive Cancer Center · Rochester, Minnesota
- JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCCPHASE3 · Recruiting · Johnson & Johnson Enterprise Innovation Inc. · Birmingham, Alabama
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCCPHASE1 · Recruiting · Melissa Pugliano-Mauro · Pittsburgh, Pennsylvania